The Efficacy of Oral Ivabradine in Patients Presenting With Acute Non ST-segment Elevation Myocardial Infarction (NSTEMI): Interventional Randomized Parallel Study
Overview
- Phase
- Phase 2
- Intervention
- Ivabradine
- Conditions
- NSTEMI
- Sponsor
- Cairo University
- Enrollment
- 100
- Primary Endpoint
- Heart Rate
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
This study aims to evaluate the beneficial effect of heart rate reduction of oral ivabradine in patients presenting with non ST-segment elevation myocardial infarction (NSTEMI) during acute stage post percutaneous coronary intervention versus conventional treatment.
Materials and methods: A total of 100 patients admitted to the emergency department, National Heart Institute, Cairo, Egypt were randomized into two groups as follows: Group A: 50 patients with NSTEMI treated with ivabradine (5mg twice daily) in addition to the conventional treatment; Group B: 50 patients with NSTEMI treated with the conventional treatment only. Demographic data, detailed history, clinical examination, chest pain onset, blood pressure, heart rate (HR), temperature and respiratory rate, electrocardiogram (ECG) as well as echocardiography and laboratory investigations were recorded. Patients were monitored for a period of 3-5 days (acute stage).
Investigators
Samar Farghali Farid
Professor and Head of Clinical Pharmacy Department
Cairo University
Eligibility Criteria
Inclusion Criteria
- •Patients with NSTEMI with normal sinus rhythm and heart rate (HR) more than 70 beats per minute (bpm) and systolic blood pressure (SBP) \>90 mm Hg undergoing PCI
Exclusion Criteria
- •Patients needing urgent cardiac surgery, IV inotropic agents or had a HR less than 60 bpm without any medication.
Arms & Interventions
Group A Ivabradine Group
Intervention: Ivabradine
Group B Control Group
Intervention: Ivabradine
Group B Control Group
Intervention: Conventional Treatment
Outcomes
Primary Outcomes
Heart Rate
Time Frame: acute stage post percutaneous coronary intervention (3-5 days)
Heart Rate Reduction